OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the sale, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. The trade was a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
OrthoPediatrics Trading Up 1.8 %
Shares of KIDS traded up $0.46 during trading hours on Tuesday, hitting $25.42. 138,044 shares of the stock traded hands, compared to its average volume of 162,840. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The firm has a market capitalization of $617.38 million, a PE ratio of -20.67 and a beta of 1.22. The business has a fifty day moving average of $24.74 and a 200-day moving average of $25.62.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.
Hedge Funds Weigh In On OrthoPediatrics
Analysts Set New Price Targets
Several analysts have recently commented on the company. Stifel Nicolaus decreased their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Truist Financial decreased their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th.
Check Out Our Latest Analysis on KIDS
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Further Reading
- Five stocks we like better than OrthoPediatrics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How to Use the MarketBeat Stock Screener
- 3 Must-Own Stocks to Build Wealth This Decade
- P/E Ratio Calculation: How to Assess Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.